Cargando…

Noncanonical regulation of imprinted gene Igf2 by amyloid-beta 1–42 in Alzheimer’s disease

Reduced insulin-like growth factor 2 (IGF2) levels in Alzheimer’s disease (AD) may be the mechanism relating age-related metabolic disorders to dementia. Since Igf2 is an imprinted gene, we examined age and sex differences in the relationship between amyloid-beta 1–42 (Aβ(42)) accumulation and epige...

Descripción completa

Detalles Bibliográficos
Autores principales: Fertan, Emre, Gendron, William H., Wong, Aimée A., Hanson, Gabrielle M., Brown, Richard E., Weaver, Ian C. G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9899226/
https://www.ncbi.nlm.nih.gov/pubmed/36739453
http://dx.doi.org/10.1038/s41598-023-29248-x
_version_ 1784882597360304128
author Fertan, Emre
Gendron, William H.
Wong, Aimée A.
Hanson, Gabrielle M.
Brown, Richard E.
Weaver, Ian C. G.
author_facet Fertan, Emre
Gendron, William H.
Wong, Aimée A.
Hanson, Gabrielle M.
Brown, Richard E.
Weaver, Ian C. G.
author_sort Fertan, Emre
collection PubMed
description Reduced insulin-like growth factor 2 (IGF2) levels in Alzheimer’s disease (AD) may be the mechanism relating age-related metabolic disorders to dementia. Since Igf2 is an imprinted gene, we examined age and sex differences in the relationship between amyloid-beta 1–42 (Aβ(42)) accumulation and epigenetic regulation of the Igf2/H19 gene cluster in cerebrum, liver, and plasma of young and old male and female 5xFAD mice, in frontal cortex of male and female AD and non-AD patients, and in HEK293 cell cultures. We show IGF2 levels, Igf2 expression, histone acetylation, and H19 ICR methylation are lower in females than males. However, elevated Aβ(42) levels are associated with Aβ(42) binding to Igf2 DMR2, increased DNA and histone methylation, and a reduction in Igf2 expression and IGF2 levels in 5xFAD mice and AD patients, independent of H19 ICR methylation. Cell culture results confirmed the binding of Aβ(42) to Igf2 DMR2 increased DNA and histone methylation, and reduced Igf2 expression. These results indicate an age- and sex-related causal relationship among Aβ(42) levels, epigenomic state, and Igf2 expression in AD and provide a potential mechanism for Igf2 regulation in normal and pathological conditions, suggesting IGF2 levels may be a useful diagnostic biomarker for Aβ(42) targeted AD therapies.
format Online
Article
Text
id pubmed-9899226
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-98992262023-02-06 Noncanonical regulation of imprinted gene Igf2 by amyloid-beta 1–42 in Alzheimer’s disease Fertan, Emre Gendron, William H. Wong, Aimée A. Hanson, Gabrielle M. Brown, Richard E. Weaver, Ian C. G. Sci Rep Article Reduced insulin-like growth factor 2 (IGF2) levels in Alzheimer’s disease (AD) may be the mechanism relating age-related metabolic disorders to dementia. Since Igf2 is an imprinted gene, we examined age and sex differences in the relationship between amyloid-beta 1–42 (Aβ(42)) accumulation and epigenetic regulation of the Igf2/H19 gene cluster in cerebrum, liver, and plasma of young and old male and female 5xFAD mice, in frontal cortex of male and female AD and non-AD patients, and in HEK293 cell cultures. We show IGF2 levels, Igf2 expression, histone acetylation, and H19 ICR methylation are lower in females than males. However, elevated Aβ(42) levels are associated with Aβ(42) binding to Igf2 DMR2, increased DNA and histone methylation, and a reduction in Igf2 expression and IGF2 levels in 5xFAD mice and AD patients, independent of H19 ICR methylation. Cell culture results confirmed the binding of Aβ(42) to Igf2 DMR2 increased DNA and histone methylation, and reduced Igf2 expression. These results indicate an age- and sex-related causal relationship among Aβ(42) levels, epigenomic state, and Igf2 expression in AD and provide a potential mechanism for Igf2 regulation in normal and pathological conditions, suggesting IGF2 levels may be a useful diagnostic biomarker for Aβ(42) targeted AD therapies. Nature Publishing Group UK 2023-02-04 /pmc/articles/PMC9899226/ /pubmed/36739453 http://dx.doi.org/10.1038/s41598-023-29248-x Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Fertan, Emre
Gendron, William H.
Wong, Aimée A.
Hanson, Gabrielle M.
Brown, Richard E.
Weaver, Ian C. G.
Noncanonical regulation of imprinted gene Igf2 by amyloid-beta 1–42 in Alzheimer’s disease
title Noncanonical regulation of imprinted gene Igf2 by amyloid-beta 1–42 in Alzheimer’s disease
title_full Noncanonical regulation of imprinted gene Igf2 by amyloid-beta 1–42 in Alzheimer’s disease
title_fullStr Noncanonical regulation of imprinted gene Igf2 by amyloid-beta 1–42 in Alzheimer’s disease
title_full_unstemmed Noncanonical regulation of imprinted gene Igf2 by amyloid-beta 1–42 in Alzheimer’s disease
title_short Noncanonical regulation of imprinted gene Igf2 by amyloid-beta 1–42 in Alzheimer’s disease
title_sort noncanonical regulation of imprinted gene igf2 by amyloid-beta 1–42 in alzheimer’s disease
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9899226/
https://www.ncbi.nlm.nih.gov/pubmed/36739453
http://dx.doi.org/10.1038/s41598-023-29248-x
work_keys_str_mv AT fertanemre noncanonicalregulationofimprintedgeneigf2byamyloidbeta142inalzheimersdisease
AT gendronwilliamh noncanonicalregulationofimprintedgeneigf2byamyloidbeta142inalzheimersdisease
AT wongaimeea noncanonicalregulationofimprintedgeneigf2byamyloidbeta142inalzheimersdisease
AT hansongabriellem noncanonicalregulationofimprintedgeneigf2byamyloidbeta142inalzheimersdisease
AT brownricharde noncanonicalregulationofimprintedgeneigf2byamyloidbeta142inalzheimersdisease
AT weaveriancg noncanonicalregulationofimprintedgeneigf2byamyloidbeta142inalzheimersdisease